Omnicell, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Allen Lutz from Bank of America Securities reiterated a Hold rating on the stock and has a $53.00 price target.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Allen Lutz has given his Hold rating due to a combination of factors related to Omnicell’s operating backdrop and valuation. He notes that capital spending conditions and pharmacy IT budgets are gradually getting better, which should support Omnicell’s new product cycle and help bookings growth accelerate. At the same time, current pharmacy IT growth expectations remain below longer-term averages, and overall capital spending, while improving, is not yet robust enough to justify a more aggressive stance. Lutz also highlights that Omnicell’s customers show a clear tendency to stay with the company and are more inclined than competitors’ clients to upgrade existing dispensing cabinets, particularly via XTExtend rather than full TitanXT conversions, which supports a steady but not explosive growth outlook.
Moreover, these improving but still moderate trends lead Lutz to view the risk/reward as balanced at current trading levels. He raises his price objective to $53 from $46, reflecting higher confidence in future bookings and applying a higher EV/EBITDA multiple based on 2026 estimates. However, because the upside from the current share price appears limited and the recovery in budgets and capital spending is incremental rather than dramatic, he stops short of recommending a Buy. Altogether, the mix of better fundamentals, modest growth expectations, and relatively full valuation supports maintaining a Neutral (Hold) rating on Omnicell’s stock.
In another report released today, TipRanks – DeepSeek also reiterated a Hold rating on the stock with a $54.00 price target.